Topcon DRI OCT Triton With SS-OCT Angio Software Evaluation Study

Completed

Conditions studied: Fluorescein Angiography Imaging

In brief

Comparisons for vascular structure visualization in the retina and choroid.

Key facts

Study ID

NCT04201340

Run by

Topcon Corporation

People needed

211

Starts

2019-12-11

Expected to finish

2022-10-20

Last updated by the study team

2022-12-08

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Subjects unable to tolerate ophthalmic imaging
• Subjects with ocular media not sufficiently clear to obtain acceptable OCT-A scans
• Subjects with known allergy to fluorescein, or subjects having liver disease, or end-stage renal disease
• Narrow angle
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine or chloroquine
• Subjects where the study eye was treated after screening and before imaging
• RETINAL GROUP Inclusion Criteria
• Subjects 22 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• Subjects who have not participated in the DRI OCT Triton with SS OCT Angio software Evaluation Prestudy
• BCVA 20/400 or better in the study eye
• Diagnosis of some type of retinal pathology likely to present in the vasculature in at least one eye as determined by the investigator, may include, but is not limited to: Diabetic retinopathy, Retinal Vein occlusions, Exudative AMD or Macular telangiectasia with expected presentation in the vasculature of, including but not limited to, microaneurysms, capillary dropout and/or choroidal neovascularization.
• Exclusion Criteria
• Subjects unable to tolerate ophthalmic imaging
• Subjects with ocular media not sufficiently clear to obtain acceptable OCT-A scans
• Subjects with known allergy to fluorescein or if ICGA is clinically indicated, indocyanine green dyes, shellfish, iodine, or subjects having liver disease, or end-stage renal disease
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine or chloroquine
• Subjects where the study eye was treated after screening and before imaging

Where it is running

• Southeast Retina Center — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.